Investigation of the interaction between argatroban and acetaminophen, lidocaine, or digoxin

被引:16
作者
Inglis, AML
Sheth, SB
Hursting, MJ
Tenero, DM
Graham, AM
DiCicco, RA
机构
[1] GSK, Thrombosis Clin Dev & Prod Strategy, Collegeville, PA USA
[2] GSK, Clin Pharmacol & Expt Med, King Of Prussia, PA USA
[3] GSK, Clin Pharmacol Stat & Data Sci, Philadelphia, PA USA
[4] GSK, Clin Pharmacol Study Management, Philadelphia, PA USA
关键词
acetaminophen; analgesics and antipyretics; anesthetics; local; anticoagulants; argatroban; cardiac drugs; digoxin; drug interactions; lidocaine hydrochloride; pharmacokinetics;
D O I
10.1093/ajhp/59.13.1258
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The potential pharmacokinetic interactions between argatroban and acetaminophen, lidocaine, or digoxin were examined. Three randomized crossover studies were conducted. In the first study, 11 subjects completed three sessions (with a five-day washout period between sessions), receiving two 500-mg acetaminophen caplets at 0, 6,12,18, and 24 hours; i.v. argatroban 1.5 mug/kg/min from hours 12 to 30; or a combination of both. In the second study, 12 subjects completed three sessions (with a five-day washout period between sessions), receiving lidocaine hydrochloride injection 2 mg/kg/hr for 16 hours (after receiving a loading dose of 1.5 mg/kg over 10 minutes), i.v. argatroban 1.5 mug/kg/min for 16 hours, or a combination of both. In the third study, 12 subjects completed two sessions (with a seven-day washout period between sessions), receiving oral digoxin 0.375 mg/day for 15 days and either i.v. placebo or argatroban 2 mug/kg/min on days 11 through 15. Primary pharmacokinetic values in each study included area under the drug concentration versus time curve and steady-state concentrations of argatroban and the concomitantly administered drug. Lack of a pharmacokinetic interaction (individually defined for each study) was demonstrated in each study. Argatroban, regardless of acetaminophen or lidocaine administration, prolonged activated partial thromboplastin time values approximately 1.6-1.8 times the baseline values. No deaths, unexpected adverse events, or clinically significant changes in safety laboratory values occurred. No pharmacokinetic interaction was detected between argatroban and acetaminophen, lidocaine, or digoxin. Argatroban is well tolerated during coadministration with these drugs. In practice, argatroban coadministered with these frequently prescribed drugs should require no dosage adjustments.
引用
收藏
页码:1258 / 1266
页数:9
相关论文
共 12 条
[1]   LIDOCAINE METABOLISM IN HUMAN-LIVER MICROSOMES BY CYTOCHROME-P450IIIA4 [J].
BARGETZI, MJ ;
AOYAMA, T ;
GONZALEZ, FJ ;
MEYER, UA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (05) :521-527
[2]  
HAUSCHKE D, 1990, INT J CLIN PHARM TH, V28, P72
[3]   Novastan® (brand of argatroban):: A small-molecule, direct thrombin inhibitor [J].
Hursting, MJ ;
Alford, KL ;
Becker, JCP ;
Brooks, RL ;
Joffrion, JL ;
Knappenberger, GD ;
Kogan, PW ;
Kogan, TP ;
McKinney, AA ;
Schwarz, RP .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1997, 23 (06) :503-516
[4]  
Lewis BE, 2001, CIRCULATION, V103, P1838
[6]   KINETICS AND METABOLISM OF PARACETAMOL AND PHENACETIN [J].
PRESCOTT, LF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 10 :S291-S298
[7]   A COMPARISON OF THE 2 ONE-SIDED TESTS PROCEDURE AND THE POWER APPROACH FOR ASSESSING THE EQUIVALENCE OF AVERAGE BIOAVAILABILITY [J].
SCHUIRMANN, DJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1987, 15 (06) :657-680
[8]  
*SMITHKL BEECH, 2000, ARG PACK INS
[9]   Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects [J].
Swan, SK ;
St Peter, JV ;
Lambrecht, LJ ;
Hursting, MJ .
PHARMACOTHERAPY, 2000, 20 (07) :756-770
[10]   The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction [J].
Swan, SK ;
Hursting, MJ .
PHARMACOTHERAPY, 2000, 20 (03) :318-329